Mounjaro and the Contraceptive Injection: what changes, what doesn't

The misconception that worries most people

A lot of people arrive at this question assuming Mounjaro interferes with all contraception. That worry is understandable, there has been a great deal of coverage about GLP-1 medicines and the pill, and the concern has bled across to every method people can think of. The truth is more specific.

The interaction that prompted NHS guidance centres on oral contraceptive pills. Tirzepatide slows the rate at which your stomach empties, which can reduce the speed and completeness with which a swallowed tablet is absorbed. The result is that the pill's blood concentration may be lower than usual, especially in the early weeks of Mounjaro treatment and after each dose increase.

Mounjaro itself is a subcutaneous injection, and injectable contraceptives work on the same principle of bypassing the digestive system altogether. Depo-Provera (medroxyprogesterone acetate) is administered by a healthcare professional into the muscle; Sayana Press is given as a subcutaneous injection. Neither reaches your bloodstream via the gut, so the gastric-emptying mechanism simply does not apply. NHS England's guidance on weight management injections confirms this distinction when setting out which contraceptive methods may need additional cover.

One short sentence that is worth sitting with: the pill question is real, but it is not your question here.

What the guidance actually says about contraception during tirzepatide treatment

For completeness, the UK position on contraception and Mounjaro is this. Women using oral contraceptive pills should use an additional non-oral method (for example, condoms) during the first four weeks of Mounjaro treatment and for four weeks after each dose step up. This is because absorption of the pill can be reduced during that window. The guidance, referenced by NHS Scotland's medicines information pages, draws a clear line around orally administered hormones.

Injectable methods (both intramuscular and subcutaneous) do not fall under this additional-cover instruction. If the contraceptive injection is your only method, there is no equivalent directive to add a barrier method. Your existing schedule (typically every 12 or 13 weeks depending on the product) continues as normal.

That said, a prescriber reviewing your case may want to discuss your contraceptive history as part of a thorough consultation, particularly if you have recently switched methods or if your injection is overdue. The right person to confirm this is a clinician who can see your full history, not a general information page. If you have questions about Mounjaro and Depo-Provera specifically, that page goes into more depth on the Depo-Provera pathway.

Pregnancy, breastfeeding and planning ahead

Tirzepatide is not recommended during pregnancy, while breastfeeding, or for anyone actively trying to conceive. The MHRA advises that women use effective contraception throughout treatment and for a wash-out period after stopping before attempting conception. The duration of that wash-out should be confirmed with your prescriber, who will factor in your treatment history.

If you become pregnant while using Mounjaro, stop treatment and contact your GP or midwife promptly. The same applies if you are breastfeeding and considering starting treatment, it is not recommended, and a prescriber can help you think through the timing. These are the clearest lines in the guidance, and they apply regardless of which contraceptive method you use.

For those considering Mounjaro for weight management but who plan to start a family in the next year or two, that timeline is something to raise early in a consultation, so it can be factored into the treatment plan from the start. You can read more about the broader treatment context on the Mounjaro overview page.

Practical questions to raise before starting treatment

Even where the evidence is reassuring (as it is for the contraceptive injection) a number of practical points are worth raising with your prescriber. When is your next injection due? Has your cycle changed in a way that might affect how you track things? Are you on any other medicines that interact with either tirzepatide or your contraceptive? These are the kinds of questions a thorough consultation should surface.

If you are thinking about how to give the injection correctly, or where to rotate sites, our guidance on how to give the Mounjaro injection covers technique in detail, and the most effective injection sites page addresses rotation. Minor site reactions are common in the first weeks, if you notice redness or itching, the injection site reactions page explains what is typical and what warrants a call to your prescriber.

At nume, every consultation is read by a GPhC-registered Independent Prescriber, a real clinician who looks at your answers, not software running through a checklist. If contraception is part of your picture, it belongs in that conversation. Start your free consultation and our clinical team will work through it with you.